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The production of phages for therapeutic purposes demands fast, efficient and scalable
purification procedures. Phage lysates have a wide range of impurities, of which
endotoxins of gram-negative bacteria and protein toxins produced by many pathogenic
bacterial species are harmful to humans. The highest allowed endotoxin concentration
for parenterally applied medicines is 5 EU/kg/h. The aim of this study was to evaluate
the feasibility of different purification methods in endotoxin and protein toxin removal
in the production of phage preparations for clinical use. In the purification assays,
we utilized three phages: Escherichia phage vB_EcoM_fHoEco02, Acinetobacter
phage vB_ApiM_fHyAci03, and Staphylococcus phage vB_SauM_fRuSau02. The
purification methods tested in the study were precipitation with polyethylene glycol,
ultracentrifugation, ultrafiltration, anion exchange chromatography, octanol extraction,
two different endotoxin removal columns, and different combinations thereof. The
efficiency of the applied purification protocols was evaluated by measuring phage
titer and either endotoxins or staphylococcal enterotoxins A and C (SEA and SEC,
respectively) from samples taken from different purification steps. The most efficient
procedure in endotoxin removal was the combination of ultrafiltration and EndoTrap
HD affinity column, which was able to reduce the endotoxin-to-phage ratio of
vB_EcoM_fHoEco02 lysate from 3.5 × 104 Endotoxin Units (EU)/109 plaque forming
units (PFU) to 0.09 EU/109 PFU. The combination of ultrafiltration and anion exchange
chromatography resulted in ratio 96 EU/109 PFU, and the addition of octanol extraction
step into this procedure still reduced this ratio threefold. The other methods tested either
resulted to less efficient endotoxin removal or required the use of harmful chemicals that
should be avoided when producing phage preparations for medical use. Ultrafiltration
with 100,000 MWCO efficiently removed enterotoxins from vB_SauM_fRuSau02 lysate
(from 1.3 to 0.06 ng SEA/109 PFU), and anion exchange chromatography reduced the
enterotoxin concentration below 0.25 ng/ml, the detection limit of the assay.
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INTRODUCTION
The antibiotic resistance of pathogenic bacteria is recognized as one of the major global health
threats of our time (World Health Organization [WHO], 2018). Some experts even state that we
are already entering a post-antibiotic era, where medical treatments such as operations need to be
reconsidered due to high risk of infection (Fowler et al., 2014). Phage therapy, i.e., the treatment of
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bacterial infections with bacteriophages, is one of the possible
alternative therapies that can be used to cure patients for
whom antibiotics are not an option (Kutter et al., 2010, 2015;
Abedon et al., 2011).
Phages themselves are considered safe for humans (Speck
and Smithyman, 2016). However, phage lysates may contain
many kinds of harmful by-products, especially endotoxins of
gram-negative bacteria and protein toxins produced by many
pathogenic bacterial species. Endotoxins are composed of Lipid
A, the hydrophobic anchor of lipopolysaccharides (LPS) forming
the outmost layer of gram-negative bacteria. Endotoxins are
highly immunogenic and if present in large quantities, they
may via cytokine signaling cause septic (endotoxic) shock
leading to intravascular coagulation, multiple organ failure,
and even death (Raetz and Whitfield, 2002). The endotoxin
levels in medicinal products are strictly regulated, the highest
permitted amount being 5.0 Endotoxin Units (EU)/kg/h
for intravenous and 0.2 EU/kg/h for intrathecal products
(Council of Europe, 2005).
Many pathogenic bacteria produce protein toxins
that they excrete into their environment. These toxins
are often important virulence factors and they have a
wide variety of effects in humans, depending on the
bacterial species and the type of infection. Examples of
bacterial toxins include Shiga toxin of Escherichia coli
(Plunkett et al., 1999; Chou et al., 2013), botulinum toxin
of Clostridium botulinum (Poulain and Popoff, 2019),
and enterotoxins of Staphylococcus aureus (Betley and
Mekalanos, 1985; Dinges et al., 2000). Bacterial toxins
are often extremely potent, amounts as small as tens to
hundreds of nanograms can cause disease (Asao et al., 2003;
Pirazzini et al., 2017).
The traditional way to purify phages is PEG precipitation
followed by several rounds of chloroform extractions,
ultracentrifugation with cesium chloride (CsCl) gradient,
and finally dialysis to remove CsCl. For therapeutic purposes,
this is a problematic approach for several reasons: First,
the amount of chloroform is strictly regulated in medical
products and, according to ICH harmonized guideline
Q3C(R6), the permissible daily exposure should not exceed
0.6 mg/day. Therefore, the use of chloroform would
necessitate the analysis of residual solvent concentration.
Second, also CsCl is considered safety risk (Food and
Drug Administration., 2018), even though the residual
CsCl concentration in phage products would probably be
irrelevant (Guerin et al., 2015). Third, this process is very
laborious and slow.
More recently, several alternative purification methods have
been applied. Szermer-Olearnik and Boratynski (2015) showed
that extraction with 1-octanol efficiently removed endotoxins
from phage lysates (Szermer-Olearnik and Boratynski, 2015).
Later, Bonilla et al. (2016) developed the method further by
introducing a vacuum-based method to remove the residual
solvent. The phage recoveries in these two studies were
typically ∼50%. Extraction with the detergent deoxycholate
(DOC) was shown to remove LPS from phage preparation
without significant reduction in phage titers (Hashemi et al.,
2013), but the harmfulness of DOC to humans may limit
its use for therapeutic purposes. A number of studies have
shown that different chromatographic methods can be used to
purify phages. Anion exchange chromatography with monolithic
columns having weak (DEAE) or strong (QA) anion exchange
resins is a widely applied chromatographic method, with
usually fairly good phage recovery (Smrekar et al., 2008,
2011; Adriaenssens et al., 2012). However, the emphasis in
these studies done with anion exchange chromatography has
mostly been in the phage yield, and the endotoxin removal
has not been examined. Boratynski et al. (2004) showed
that a protocol containing ultrafiltration, gel filtration and
cellufine sulfate -based affinity chromatography produced a
phage preparation with very low endotoxin concentration, but
the phage yield in the process was less than 3% (Boratynski
et al., 2004). Commercial endotoxin removal columns have also
been used to purify phages, however, the results have been
somewhat confusing. Merabishvili et al. (2009) used EndoTrap
Blue column to remove endotoxins from a therapeutic phage
cocktail, but as the authors found the Limulus amoebocyte
lysate (LAL) endotoxin analysis kit inappropriate for phage
products, the outcome was only measured with pyrogenicity
assay using rabbits (Merabishvili et al., 2009). In another study
by Cooper et al. (2014), the purification of a Pseudomonas
aeruginosa phage cocktail with the EndoTrap Blue column
resulted only in a minimal reduction of the endotoxin levels
(Cooper et al., 2014). As shown in the aforementioned
examples, phage purification studies done so far have mostly
focused on phage yield and endotoxin removal. To our
knowledge, there are no studies showing how bacterial toxins
are removed from phage preparations during the phage
purification process.
The aim of this work was to study the applicability of the
different phage purification methods in the preparation of
clinical phage products. We wanted to establish a purification
process that would efficiently remove endotoxins and bacterial
protein toxins while retaining high phage yield. In addition
to the phage recovery and product purity, our criteria for the
process optimization were the laboriousness of the process and
the possibility for scaling-up. The methods tested for purification
were precipitation with polyethylene glycol, ultracentrifugation,
ultrafiltration, anion exchange chromatography, octanol
extraction, two different endotoxin removal columns, and
different combinations thereof. The endotoxin removal
experiments were mostly performed with an Escherichia
phage vB_EcoM_fHoEco02, a member of Tequatrovirus genus
(Kiljunen et al., 2018). To study whether the endotoxin affinity
columns can also remove endotoxins of other gram-negative
bacteria than E. coli, confirmatory tests were done with
vB_ApiM_fHyAci03 infecting Acinetobacter pittii (Pulkkinen
et al., 2019). Since LAL endotoxin measurement kit is sensitive to
impurities often present in phage products, we used EndoLISA
assay (Hyglos) which is supposed to be less error-prone. To
analyze the removal of protein toxins from phage preparation,
we utilized staphylococcal phage vB_SauM_fRuSau02 grown in
a S. aureus strain known to produce staphylococcal enterotoxins
(Leskinen et al., 2017).
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MATERIALS AND METHODS
Bacterial Strains, Phages and Media
Three clinical bacterial strains obtained from The Hospital
District of Helsinki and Uusimaa Laboratories (HUSLAB),
Finland, were used in this work: E. coli 123738 (Kiljunen
et al., 2018), A. pittii #5565 (Pulkkinen et al., 2019) and
S. aureus 13KP (Leskinen et al., 2017). The phages cultured in
these strains were vB_EcoM_fHoEco02 (fHoEco02) (Kiljunen
et al., 2018), vB_ApiM_fHyAci03 (fHyAci03) (Pulkkinen et al.,
2019), and vB_SauM_fRuSau02 (fRuSau02) (Leskinen et al.,
2017), respectively.
All bacterial and phage incubations were carried out at 37◦C
using Luria Broth (LB) medium (Sambrook and Russell, 2001).
Soft agar medium included additionally 0.4% (w/v) agar (Becton
Dickinson), and LB agar plates were solidified with 1.5% (w/v)
of agar. fHoEco02 and fHyAci03 lysates were produced by liquid
culture method and fRuSau02 lysate from semiconfluent plates
otherwise as described elsewhere (Sambrook and Russell, 2001)
but without using chloroform. All phage lysates were filtered
through 0.22 µm PES Rapid Flow Bottle Top filter (Nalgene).
Unless otherwise stated, SM buffer (100 mM NaCl, 10 mM
MgSO4, 50 mM Tris–HCl, pH 7.5, and 0.01% (w/v) gelatin)
(Sambrook and Russell, 2001) was used as phage buffer.
Phage Purification
PEG Precipitation, Ultrafiltration, and
Ultracentrifugation
Phage precipitation with PEG 8000 and subsequent chloroform
extractions were done as described elsewhere (Sambrook and
Russell, 2001). Briefly: 30 ml of fHoEco02 lysate was treated with
NaCl (1M), RNAseA (1.2 µg/ml) DNAseI (1 µg/ml) for 1 h on
ice, after which the solution was centrifuged with Avanti J-26 XPI
centrifuge (Beckman Coulter) at 8,739× g and+4◦C for 20 min.
8 g of PEG was dissolved in the supernatant and the solution was
incubated o/n at +4◦C. The solution was centrifuged as above
and the pellet was dissolved into 5 ml of TM buffer (10 mM
MgSO4, 50 mM Tris, and pH 7.5). The solution was extracted
with 1 VOL chloroform for four times, and the centrifugations
were done with Sl-16R centrifuge (Thermo scientific) at 3500× g
and RT for 17 min.
For ultrafiltration, Vivaspin ultrafiltration columns
with 100,000 MWCO polyethersulfone (PES) membrane
(Sartorius) were used. The phage samples were concentrated by
centrifugation to one tenth of the initial volume and washed by
restoring the original volume with a desired buffer and repeating
the centrifugation step. Finally, the original volume was restored
by adding the same buffer as was used for washing. The samples
were centrifuged at 3500 × g at RT using the Sl-16R centrifuge
(Thermo scientific).
For ultracentrifugation through sucrose density gradient, 2 ml
of PEG-precipitated or ultrafiltrated phage sample was layered on
top of 3 ml of pre-formed 5–20% sucrose gradient. The samples
were centrifuged at 194,432× g and+4◦C for 2 h with Optima L-
80 XP ultracentrifuge and SW55Ti rotor (Beckman Coulter), after
which the phage pellet was resuspended into 500µl of SM-buffer.
Extraction With 1-Octanol
Extraction with 1-octanol was basically carried out as described
earlier (Szermer-Olearnik and Boratynski, 2015). 7 ml of phage
lysate was treated with 5 ml of 99% 1-octanol (Acros organics)
and the phases were separated by centrifuging at 4,000 × g and
+4◦C for 10 min. The removal of octanol was enhanced by
repeating the centrifugation step two additional times.
Anion Exchange Chromatography
Prior to anion exchange chromatography (AEX), 5 ml of phage
lysate or 4 ml of octanol-treated phage lysate was ultrafiltrated
to 1 volume of chromatography buffer (20 mM Tris–HCl, pH
7.5) as above and filtered with 0.2 µm Minisart RC Syringe
Filter (Sartorius). For AEX, CIM QA-1 tube monolithic column
with 6-µm pore size (BIA Separations) and Äkta Purifier
(GE Healthcare) were used. The run conditions for fHoEco02
were optimized by running a linear NaCl gradient in the
chromatography buffer and determining the NaCl concentration
that was needed to elute the phage; the conditions for fRuSau02
runs were determined earlier (Leskinen et al., 2017). To purify
fHoEco02, 900 µl of ultrafiltrated phage solution was injected
into the column. In purification schemes where the AEX purified
phages were further purified with endotoxin affinity columns, 1.8
and 3.0 ml of ultrafiltrated fHoEco02 solutions were applied to
AEX prior to EndoTrap HD and Pierce columns, respectively.
A step gradient with chromatography buffer having 260 and
350 mM NaCl was used to wash and elute the phage, respectively.
For fRuSau02, a 500-µl sample was injected into the column.
350 mM NaCl was used for washing and 550 mM NaCl for
elution. 1 ml fractions were collected throughout the runs.
The phage fractions (3–4 ml in total) were pooled, a 100 to
150-µl sample was withdrawn for analysis, and the remaining
phage sample was ultrafiltrated into SM buffer to a volume
corresponding to the volume that was injected in the column.
Endotoxin Affinity Columns
Two commercial endotoxin affinity columns were used for
endotoxin removal: EndoTrap HD 1 ml column (LIONEX)
and Pierce high-capacity endotoxin removal spin 1 ml column
(Thermo Scientific). For EndoTrap HD, 750 µl of ultrafiltrated
or AEX purified phage in SM buffer supplemented with 0.1 mM
CaCl2 was run through the column using gravity flow. The void
volume of 300 µl was taken in a separate tube, after which the
phage sample of ∼1.3 ml was collected. For Pierce column, 5 ml
of ultrafiltrated phage lysate in SM buffer supplemented with
400 mM, NaCl, or 2 ml of AEX -purified and ultrafiltrated phage
in the same buffer was applied in the column and incubated at
+4◦C for 1 h. Approximately 4.8 ml of the phage solution was
collected by centrifugation at 500× g at RT for 1 min.
The Analysis of Phage Samples
Every purification scheme in this study was repeated three
individual times. The phage titer and endotoxin concentration
of samples taken from every step were determined, and mean
and standard deviation (SD) of the results were calculated.
Phage titers were determined with the standard double-layer
assay as described elsewhere (Sambrook and Russell, 2001).
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FIGURE 1 | PEG precipitation and sucrose gradient ultracentrifugation in fHoEco02 purification. fHoEco02 was purified by a protocol consisting of PEG precipitation,
ultracentrifugation, and ultrafiltration (A) or of ultrafiltration, ultracentrifugation, and ultrafiltration (B). The graph shows endotoxin concentration as endotoxin unit
(EU)/109 PFU. Each procedure was repeated three individual times; the columns indicate the mean and error bars indicate standard deviation (SD). PEG, PEG
precipitation; UF, ultrafiltration; UC, ultracentrifugation.
FIGURE 2 | Anion exchange chromatography and 1-octanol extraction in fHoEco02 purification. fHoEco02 was purified by a protocol consisting of ultrafiltration,
anion exchange chromatography, and ultrafiltration (A) or 1-octanol extraction, ultrafiltration, anion exchange chromatography, and ultrafiltration. (B) The graph
shows endotoxin concentration as endotoxin unit (EU)/109 PFU. Each procedure was repeated three individual times; the columns indicate the mean and error bars
indicate standard deviation (SD). 1-oc, extraction with 1-octanol, UF, ultrafiltration; AEX, anion exchange chromatography.
Endotoxin concentrations were determined with EndoLISA assay
(Hyglos) and staphylococcal enterotoxins were measured with
RIDASCREEN R© SET A–E kit (r-biopharm) using staphylococcal
enterotoxin A (Merck) and C2 (Abcam) as standards. For both
assays, fluorescence values were measured using HIDEX sense
microplate reader with 0.5.35.0 platereader software (Hidex).
RESULTS
Removal of E. coli Endotoxins by PEG
Precipitation and Sucrose Gradient
Ultracentrifugation
The traditional procedure for phage purification is the
combination of PEG precipitation, chloroform extractions, and
CsCl gradient ultracentrifugation. Since the use of chloroform
should be avoided in phage preparations intended for medical
use, we wanted to test whether ultrafiltration can replace
PEG precipitation as the pre-purification/concentration
step. To circumvent the potential health hazards associated
with CsCl, we used sucrose gradient instead of CsCl in
the ultracentrifugation.
PEG precipitation reduced the endotoxin-to-phage ratio of
fHoEco02 by ∼20 fold (Figure 1A and Supplementary Table
S1), whereas ultrafiltration only by four-fold (Figure 1B and
Supplementary Table S1). Thus, ultrafiltration was not as
efficient method for pre-purification as PEG precipitation.
However, as the phage recovery in ultrafiltration was
high (Supplementary Table S1), it can be used for phage
concentration and buffer exchange. Sucrose gradient
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FIGURE 3 | Endotoxin affinity columns and anion exchange chromatography in fHoEco02 purification. fHoEco02 was purified by a protocol consisting of
ultrafiltration and EndoTrap HD column (A), ultrafiltration, anion exchange chromatography, ultrafiltration, and EndoTrap HD column (B), ultrafiltration, Pierce
high-capacity endotoxin removal spin column and ultrafiltration (C), and ultrafiltration, anion exchange chromatography, ultrafiltration, Pierce high-capacity endotoxin
removal spin column, and ultrafiltration (D). The graph shows endotoxin concentration as endotoxin unit (EU)/109 PFU. Each procedure was repeated three
individual times; the columns indicate the mean and error bars indicate standard deviation (SD). ∗The endotoxin concentration of one out of three replicates was
below the detection limit; the columns indicate the mean of two replicates and the errors indicate range. UF: ultrafiltration, AEX: anion exchange chromatography.
ultracentrifugation only reduced the endotoxin-to-phage ratio by
∼1.5-fold (Figure 1 and Supplementary Table S1). Therefore,
the endotoxin removal potential of this method was minimal.
Removal of E. coli Endotoxins by Anion
Exchange Chromatography and
1-Octanol Extraction
We then wanted to study how efficiently anion exchange
chromatography and 1-octanol extraction remove E. coli
endotoxins from phage preparation. To this end, two purification
strategies were followed: One with ultrafiltration, anion exchange
chromatography, and ultrafiltration, and another with 1-octanol
extraction preceding these three steps.
As above, ultrafiltration did not significantly remove
endotoxins from phage samples (Figure 2 and Supplementary
Table S2). Anion exchange chromatography was very efficient
in endotoxin removal. In the first purification strategy
(ultrafiltration – chromatography - ultrafiltration), the
endotoxin-to-phage ratio was lowered from 3.5 × 103 EU/109
PFU to 95.5 EU/109 PFU (Figure 2A and Supplementary Table
S2). 1-octanol extraction performed prior to the chromatography
reduced the endotoxin-to-phage ratio by ∼three-fold, and
the final EU/109 PFU after the second purification strategy
(1-octanol–ultrafiltration–chromatography–ultrafiltration), was
as low as 30.4 (Figure 2B and Supplementary Table S2).
When examining the purification results and phage
recoveries in individual purification steps of the first
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FIGURE 4 | Endotoxin affinity columns and anion exchange chromatography in fHyAci03 purification. fHyAci03 was purified by a protocol consisting of ultrafiltration
and EndoTrap HD column (A) and ultrafiltration, Pierce high-capacity endotoxin removal spin column and ultrafiltration (B). The graph shows endotoxin
concentration as endotoxin unit (EU)/109 PFU. Each procedure was repeated three individual times; the columns indicate the mean and error bars indicate standard
deviation (SD). UF, ultrafiltration.
strategy (ultrafiltration–chromatography–ultrafiltration), an
incoherent finding arose: In the first ultrafiltration step
prior to AEX, the endotoxin-to-phage ratio seemed to rise.
In addition, the phage recovery in the same step seemed
very low (Supplementary Table S2). This is probably
due to reversible aggregation of fHoEco02 in the low-salt
chromatography buffer, leading to underestimation in the
phage titer. The phenomenon of aggregation of T4 phage in
low-salt conditions was recently described by Szermer-Olearnik
et al. (2017). Interestingly, the same effect was not observed
in the second purification strategy (1-octanol–ultrafiltration–
chromatography–ultrafiltration), perhaps indicating that the
residual octanol in the phage sample prevented the aggregation.
In our hands, the phage recovery in octanol extraction was only
15% (Supplementary Table S2).
Removal of E. coli Endotoxins by
Endotoxin Affinity Columns
There are several commercial affinity columns for endotoxin
removal, and in this work, we tested two of them in the
purification of phage fHoEco02: EndoTrap HD and Pierce high-
capacity endotoxin removal spin column. Both the columns
were used either alone or in combination with ion exchange
chromatography. EndoTrap HD was extremely efficient in
the removal of E. coli endotoxins, both alone and when
used after anion exchange chromatography (Figures 3A,B and
Supplementary Tables S3, S4). Both strategies using EndoTrap
HD resulted to endotoxin-to-phage ratio of ∼0.1 EU/109 PFU,
indicating that EndoTrap HD alone was enough to remove
endotoxins from fHoEco02 lysate and the use of ion exchange
chromatography did not add to the endotoxin removal. In
contradiction, Pierce column alone did not noticeably decrease
the endotoxin-to-PFU ratio (Figure 3C and Supplementary
Table S3). When used after ion exchange chromatography, it
reduced the ratio from 32.4 to 4.1 EU/109 PFU (Figure 3D and
Supplementary Table S4), indicating that it may be used for
polishing of pre-purified phage samples.
Interestingly, the phage recoveries in all the steps producing
extremely low endotoxin-to-phage ratios (≤4 EU/109 PFU)
were>100 % (Supplementary Tables S3, S4). This discrepancy
may be due to receptor binding protein blocking ability of
soluble LPS, causing a slight underestimation of the phage
titer that is corrected when the LPS/endotoxin concentration
becomes low enough. The ability of soluble LPS to inhibit
phage T4 adsorption to the host bacteria has been shown earlier
(Washizaki et al., 2016).
Removal of A. pittii Endotoxins by
Endotoxin Affinity Columns
Since most methods for endotoxin removal have been developed
for E. coli endotoxins, we wanted to study how well the endotoxin
affinity columns can purify A. pittii phage fHyAci03. The results
shown in Figure 4 and Supplementary Table S5 indicate that
the two columns tested showed similar trend with Acinetobacter
endotoxins as with E. coli endotoxins: The combination of
ultrafiltration and EndoTrap HD reduced the endotoxin-to-
phage ratio from the 6× 103 EU/109 PFU of the raw lysate down
to 26.8 EU/109 PFU, whereas the Pierce column had practically
no effect at all. The recoveries of fHyAci03 were 143 and 58% with
EndoTrap HD and Pierce columns, respectively (Supplementary
Table S5), the>100% yield with EndoTrap HD perhaps reflecting
the decrease of the LPS inhibition of the phage.
Removal of Staphylococcal Enterotoxins
by Ultrafiltration and Anion Exchange
Chromatography
Most studies about phage purification have focused on phage
yield and endotoxin removal. However, phage lysates may also
contain protein toxins that can be potentially harmful to patients
receiving phage therapy. To study how bacterial toxins are
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removed from phage products during the purification process,
we analyzed the purification of S. aureus phage fRuSau02
cultured in a Staphylococcus strain that was earlier shown to
produce staphylococcal enterotoxins (SEs) (Leskinen et al., 2017).
The purification protocol applied here was the combination of
ultrafiltration and anion exchange chromatography. To measure
the SE concentration, we used an ELISA kit that measures
enterotoxins A, B, C, D, and E in separate wells. The kit is not
meant for quantitative analysis, but using enterotoxins A and C2
(SEA and SEC2, respectively) as standards, we found out that
the kit was linear in range 0.25 to 10 ng/ml and 0.25 to 1 ng/ml
for SEA and SEC2, respectively (not shown). According to the
manufacturer, the detection limit of the kit was 0.25 ng/ml.
As shown in Table 1, the fRuSau02 lysate contained both SEA
and SEC. Ultrafiltration reduced the ratio of both enterotoxins
to phage by ∼20-fold (from 1.3 to 0.058 ng/109 PFU for SEA
and from 3.2 to 0.22 ng/109 PFU for SEC). After anion exchange
chromatography, the SE concentrations were below the detection
limit of the kit.
DISCUSSION
Due to the increasing number of infections caused by antibiotic-
resistant bacteria, we face an urgent need for alternative therapies.
Phage therapy is a traditional method for treating bacterial
infections and it is now gaining more and more interest
throughout the world as a possible solution for this need (Abedon
et al., 2011; Kutter et al., 2015). To be safe for patients, phage
therapy products must meet several criteria with respect to
types of phages used, product purity, and the quality of their
manufacture process (Pirnay et al., 2015, 2018). The aim of this
work was to evaluate the usability of different phage purification
methods in the production of clinical-grade phage preparations.
Phages can be administered to patients by different routes,
and the purity requirements vary according to the application
route used. For parenteral administration, the highest allowed
endotoxin amount is 5 EU/kg of body weight/h. For a patient
of 70 kg, this means 8.4 × 103 EU/24 h. In a recent phage
therapy case, a daily therapeutic dose of 5 × 109 PFU was
given intravenously to a patient having severe infection caused
by Acinetobacter baumannii (Schooley et al., 2017). If we
assume this as a typical therapeutic dose, the highest acceptable
endotoxin-to-phage ratio when treating a 70-kg patient would be
1.6× 103 EU/109 PFU.
The traditional method for concentration and pre-purification
of phages from crude lysates is the precipitation with PEG
followed by several rounds of chloroform extractions. In this
study, PEG precipitation reduced the endotoxin-to-phage ratio
from 6 × 103 EU/109 PFU of the crude filtered fHoEco02
lysate down to 269 EU/109 PFU, a level sufficient for therapeutic
purposes. The phage recovery in the process was 52%. However,
since PEG needs to be removed from phage preparations by
chloroform extraction, the method cannot be recommended for
therapy purposes unless the residual chloroform concentration in
the final product is analyzed and falls below the accepted level
of 0.6 mg/day. As the alternative method for pre-purification,
concentration, and buffer exchange, we used ultrafiltration with
100,000 MWCO cut-off. UF was fast and relatively easy to scale-
up. The time consumption varied from few minutes to a couple
of hours, depending on the scale and the level of the purity of the
phage product. The ultrafiltration of crude lysates, especially the
ones prepared from semiconfluent plates, required longer time
than the buffer exchange of purified phages. Phage recoveries in
ultrafiltration were usually high, even though they varied to some
extent. Ultrafiltration was thus a usable method for concentration
and buffer exchange, but its effect in phage purification was
limited: It efficiently removed small bacterial proteins from phage
products, as demonstrated here with staphylococcal enterotoxins
A and C2. However, it only reduced the endotoxin-to-phage ratio
minimally, resulting in values ranging from 1.5 × 103 EU/109
PFU to 1.4 × 104 EU/109 PFU (Supplementary Tables S1–S4).
Therefore, ultrafiltration alone does not suffice for phages of
gram-negative bacteria if parenteral administration is needed.
Perhaps to our surprise, ultracentrifugation through
sucrose gradient was not very efficient in endotoxin removal.
However, the combination of ultrafiltration and sucrose gradient
ultracentrifugation reduced the endotoxin-to-phage ratio below
the threshold of 1.6 × 103 EU/109 PFU, indicating that a phage
product purified with this procedure might be administered
TABLE 1 | Ultrafiltration and anion exchange chromatography in fRuSau02 purification.
Lysate UF AEX UF
Titer (PFU/ml) 5.2 × 1010 ± 2.4 × 1010 2.7 × 1010 ± 8.8 × 109 5.6 × 108 ± 1.4 × 108 5.0 × 109 ± 1.6 × 109
SEA (ng/ml) 53.9 ± 5.5 1.8 ± 1.3 <0.25 <0.25
SEA (ng/109 PFU 1.3 ± 0.96 0.058 ± 0.035 – –
SEC (ng/ml) 137.9 ± 12.4 5.5 ± 1.5 <0.25 <0.25
SEC (ng/109 PFU) 3.2 ± 1.7 0.22 ± 0.063 – –
Volume in (ml) – 3.00 0.50 3.85
Volume out (ml) – 3.00 4.00 0.48
PFU in – 1.6 × 1011 ± 7.2 × 1010 1.3 × 1010 ± 4.4 × 109 2.2 × 109 ± 5.3 × 108
PFU out – 8.0 × 1010 ± 2.7 × 1010 2.3 × 109 ± 5.5 × 108 2.4 × 109 ± 7.5 × 108
Yield (%) – 54 ± 11 19 ± 8.6 108 ± 7.8
The values represent the mean and sd of three individual repetitions. Phage titers and enterotoxin concentrations indicate samples after each purification step. UF,
ultrafiltration; AEX, anion exchange chromatography; –, Not possible to calculate.
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parenterally. CsCl gradient is more commonly used than
ultrafiltration and might be more efficient in endotoxin removal.
However, as CsCl is a harmful substance (Food and Drug
Administration., 2018) and its removal from phage products
would increase the time consumption and laboriousness of the
purification procedure, we find CsCl gradient non-optimal for
medical phage production. Therefore, we did not include CsCl
gradient ultracentrifugation in this study.
The combination of anion exchange chromatography and
ultrafiltration resulted in phage preparations of high purity with
respect to endotoxins. The endotoxin-to-phage ratios after AEX
and concomitant buffer exchange by ultrafiltration were 32–
140 EU/109 PFU (Supplementary Tables S2, S4). The phage
recoveries in AEX were generally high, however, they varied
from phage to phage and even between repetitions with one
phage, which was illustrated by high standard deviations after
AEX purifications. A variation of phage recoveries with AEX
was also reported by Adriaenssens et al. (2012). The other
drawbacks of AEX are that it is rather laborious method and
needs to be optimized for each phage separately. Even though
a small-scale AEX run with the set-up utilized in this study
(1 ml monolithic column and Äkta purifier HPLC device) takes
only ∼1 h, the several washing steps required to maintain the
functionality of the system increase the time consumption to
∼1 day. In addition, GMP -certified liquid chromatography
devices are usually of industrial size, and therefore impractical
for small-scale personalized phage therapy products. AEX used as
batch purification with the ion exchange resin as a slurry might be
a conceivable alternative for the production of therapeutic phage
products, but the efficiency of the method should be tested in
practice. To conclude, we found anion exchange chromatography
to suit well for research laboratory but to be too laborious
for routine therapeutical phage purification. Extraction with 1-
octanol lowered the endotoxin-to-phage ratio by threefold and
resulted in the endotoxin-to-phage ratio of 1.3 × 103 EU/109
PFU, slightly lower than the threshold 1.6 × 103 EU/109 PFU
required for parenteral administration. The drawbacks of 1-
octanol were the low phage recovery rate (15 % with fHoEco02,
Supplementary Table S2) and the need to remove the solvent,
which slows down the process (Bonilla et al., 2016). In our hands,
the phage recoveries with octanol extractions were slightly lower
than those in earlier studies (Szermer-Olearnik and Boratynski,
2015; Bonilla et al., 2016), which may indicate that different
phages tolerate the solvent differently.
In this study, EndoTrap HD column was the optimal
way to remove endotoxins from phage preparations. The
use of the column needed only little hands-on-time and
resulted in extremely low endotoxin-to-phage ratio with high
phage recovery. In addition, the scale-up is straightforward.
The purification of E. coli phage produced lower endotoxin
concentration than that of the A. pittii phage, but even
the fHyAci03 product was pure enough for parenteral
administration. To our surprise, the Pierce endotoxin removal
column behaved very differently: Even though the phage
recoveries were good, there was only minimal improvement
in the endotoxin-to-phage ratio. The binding capacities of the
two columns, as stated by the manufacturers, were 5,000,000
and 2,000,000 EU/ml for EndoTrap HD and Pierce columns,
respectively. The total endotoxin amounts that we applied to the
columns were ∼104 EU/ml, which is clearly below the reported
limits. Therefore, the poor result with the Pierce column was
not explained by exceeding the binding capacity. Interestingly,
the outcome with the Pierce column was similar to the finding
by Cooper et al., 2014, who failed to remove endotoxins from
a phage cocktail targeting P. aeruginosa using EndoTrap Blue
column (Cooper et al., 2014). Without knowing the exact
molecules used as the affinity ligands in these columns, it is
not possible to elucidate the precise reason for their different
performance. However, we hypothesize that the affinity of the
Pierce and EndoTrap Blue columns to endotoxins is too weak
to detach LPS molecules that are attached to the tail proteins of
the phages, whereas the affinity of EndoTrap HD to endotoxins
seems to be high enough.
There are no strict limits for the concentrations of
staphylococcal enterotoxins in medical products. However,
Asao et al. (2003) estimated that 20–100 ng of enterotoxin A
was enough to cause food poisoning (Asao et al., 2003). In this
study, the enterotoxin-to-phage ratio in unpurified fRuSau02
lysate was 1.3 ng/109 PFU for SEA and 3.2 ng/109 PFU for SEC.
The therapeutic dose of 5 × 109 PFU would thus contain 6.5 ng
of SEA and 16 ng of SEC, which might cause symptoms to the
most sensitive patients when administered orally. Ultrafiltration
reduced the enterotoxin-to-phage ratio by ∼20-fold, resulting to
a phage preparation that would be safe for oral administration
with respect to enterotoxins.
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